TRML

Tourmaline Bio, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website ourmalinebio.com
Employees(FY) -
ISIN US89157D1054

Performance

-8.3%

-12.13%

-8.63%

+32.8%

-21.12%

YTD

+8.68%

Profile

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops TOUR006, a human monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The company's development pipeline also comprises medicines and therapies for the atherosclerotic cardiovascular disease (ASCVD) and thyroid eye disease (TED). Tourmaline Bio, Inc. was founded in 2021 and is headquartered in New York, New York.

Advanced Technical Analysis

Technical Analysis of TRML 2024-12-20

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 16 indicating strong downward momentum, a neutral Oscillators Score of 50 suggesting indecision, and a Technical Score of 33 reinforcing the bearish outlook. This combination signals caution for potential investors as the market appears to be struggling to g...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of TRML

Stock Rank

Recent News & Updates

2024-12-10 08:30
Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day(GlobeNewswire)
2024-12-09 19:30
Tourmaline Bio Highlights Cardiovascular Inflammation Focus and Announces Key Clinical and Strategic Updates at Investor Day(Globenewswire)
2024-11-14 07:30
Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024(GlobeNewswire)
2024-11-13 18:30
Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024(Globenewswire)
2024-11-12 23:00
Tourmaline Bio, Inc. Reports Third Quarter Financial Results(TipRanks)
2024-11-07 07:30
Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights(GlobeNewswire)
2024-11-06 18:30
Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights(Globenewswire)
2024-10-31 07:30
Tourmaline Bio to Present at Upcoming Investor Conferences(GlobeNewswire)
2024-10-30 19:30
Tourmaline Bio to Present at Upcoming Investor Conferences(Globenewswire)
2024-10-15 07:30
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024(GlobeNewswire)
2024-10-14 19:30
Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024(Globenewswire)
2024-10-11 07:30
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress(GlobeNewswire)
2024-10-10 19:30
Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress(Globenewswire)
2024-10-08 07:30
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board(GlobeNewswire)
2024-10-07 19:30
Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board(Globenewswire)
2024-09-03 07:45
Tourmaline Bio to Present at Upcoming Investor Conferences(GlobeNewswire)
2024-09-02 19:45
Tourmaline Bio to Present at Upcoming Investor Conferences(Globenewswire)
2024-08-08 08:45
Bullish Tourmaline Bio Insiders Loaded Up On US$643.3k Of Stock(Simply Wall St.)
2024-08-08 07:30
Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights(GlobeNewswire)
2024-08-07 19:30
Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights(Globenewswire)
2024-08-02 16:30
Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024(GlobeNewswire)
2024-08-02 04:30
Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024(Globenewswire)
2024-06-27 08:05
Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer(GlobeNewswire)
2024-06-26 20:05
Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer(Globenewswire)
2024-06-12 21:00
The Lustgarten Foundation Appoints Two New Board Members(Prweb)
2024-05-23 07:10
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference(GlobeNewswire)
2024-05-22 19:10
Tourmaline Bio to Present at the Jefferies Global Healthcare Conference(Globenewswire)
2024-05-16 07:00
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial(GlobeNewswire)
2024-05-15 19:00
Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial(Globenewswire)
2024-05-13 07:00
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights(GlobeNewswire)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.